BioCentury
ARTICLE | Company News

Affymetrix, Origin Technologies deal

March 28, 2016 7:00 AM UTC

Cellular and genetic analysis tools company Affymetrix said it will engage with Origin to discuss Origin’s increased proposal to acquire Affymetrix. Origin originally proposed on March 18 to acquire Affymetrix for $16.10 per share in cash; Affymetrix rejected the bid. On March 22, Origin increased its bid to $17 per share. Origin also increased its reverse termination fee to $100 million from $75 million.

Origin’s team includes former Affymetrix VP Wei Zhou, who is president and CEO of genomic analysis company Centrillion Technologies Inc. (Palo Alto, Calif.). Origin said it would have the option to combine with Centrillion if it acquires Affymetrix. ...